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PURPOSE. To identify the distribution, differential Toll-like re-
ceptor (TLR) expression, and functional contribution of mono-
cyte subpopulations in the inflammatory stage of Eales’ disease
(ED).
METHODS. Peripheral blood mononuclear cells were isolated
from nine patients during the inflammatory stage of ED and
nine age- and sex-matched healthy controls. The expression of
CD14, CD16, TLR-2, and TLR-4 on monocytes was measured by
flow cytometry. The CD14, CD16, and CD16 monocyte
populations were sorted on the basis of magnetic-activated
cell-sorting methodology, and levels of cytokines were mea-
sured by ELISA.
RESULTS. In ED patients, the number of circulating monocytes
was significantly expanded compared with that in controls
(P  0.01), with a marked increase in the nonclassic CD16
subset, which showed an activated phenotype in patients
that correlated with levels of serum proinflammatory cyto-
kines and clinical progression. A higher expression of cell
surface TLR-2 (P  0.02), but not TLR-4, was found in
monocytes of patients with ED. Furthermore, TLR-2 was
expressed at higher levels on CD16 monocytes than on
CD16 monocytes in patients, whereas no significant varia-
tion was found in TLR-4 expression on different monocyte
subsets. Peptidoglycan-induced TNF- expression correlated
with TLR-2 expression in monocytes isolated from controls
(r  0.85, P  0.0061), but not in monocytes isolated from
ED patients (r  0.553, P  0.1328).
CONCLUSIONS. These results indicate that in the pathogenesis of
ED, TLR activation and increased numbers of nonclassic
CD16 monocytes are crucial regulators, along with the secre-
tion of proinflammatory cytokines that perpetuate the inflam-
matory process in the retina. (Invest Ophthalmol Vis Sci. 2011;
52:6940–6948) DOI:10.1167/iovs.11-7834
Eales’ disease (ED) is a prototype inflammatory disorder inwhich immunogenic inflammation of the peripheral retina
leads to nonperfusion and neovascularization. At the prolifer-
ative or advanced stage of the disease, newly formed retinal
vessels are prone to develop vitreous hemorrhages resulting in
profound visual loss.1,2 Although the clinical characteristics of
the disease are well recognized, its etiopathogenesis is so far
not well defined. However, several lines of experimental evi-
dence link ED with Gram-positive bacteria, Mycobacterium
tuberculosis, and other nontuberculosis mycobacteria.3–6 Two
studies have demonstrated a statistically significant higher phe-
notype frequency of human leukocyte antigen (HLA) in ED
patients than in healthy controls7 and have identified the pres-
ence of inflammatory cells in the epiretinal membrane of pa-
tients with ED (Badrinath SS, et al. IOVS 1990;31:ARVO Ab-
stract 33). Thus, it can be hypothesized that individuals with a
predisposition to HLA, predominantly HLAB5 (B51), DR1, and
DR4, may develop retinal vasculitis as a consequence of cell-
mediated immunologic tissue damage triggered by a seques-
tered mycobacterial antigen in an inactive form that clinically
presents as ED.8
Even though most patients with ED lack clinical evidence of
infection, laboratory and clinical findings suggest the presence
of systemic inflammation in the acute phase of this disease.9,10
Therefore, it is probable that both innate and adaptive immune
systems are involved in the development of ocular inflamma-
tion. The ability of the innate immune system to recognize
microbial component–associated molecular patterns have
highlighted the central role played by one group of pattern
recognitions receptors (PRRs), the Toll-like receptors (TLRs),
in microbial recognition and host defense.11 Members of the
TLR family are expressed in a variety of cells of the innate
immune system12 and orchestrate the intracellular inflamma-
tory signaling pathways after recognition of pathogen-associ-
ated molecular patterns (PAMPs), such as bacterial cell wall
components, dsRNA, and bacterial DNA bacterial flagellin.13
Although TLR expression is primarily associated with mono-
cytes/macrophages and dendritic cells, other cells of the adap-
tive immune system and nonimmune cells have also been
shown to express TLRs.14 In fact, TLRs are capable of forming
an important bridge between the innate and adaptive immune
response by regulating expression of costimulatory molecules
on antigen-presenting cells, to drive T-cell activation, and by
creating a cytokine milieu, to conduct differentiation of T-cells
into the desired subset.15
Irrespective of any past effort to identify TLR involvement
in pathogenesis of ED, mycobacterial involvement in the patho-
genesis of the same is well studied. TLR-2 is a highly relevant
TLR in the Mycobacterium-associated pathogenic outcome
and responds to various lipoproteins and cell wall compo-
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nents, such as peptidoglycan (PGN),16–18 whereas an unde-
fined heat-labile cell–associated mycobacterial factor has been
found to be the ligand for TLR-4—hence, the relevance of
studying TLR-2 and-4 in this respect.16,19
Monocytes, too, are crucial for the immune and inflamma-
tory response, and by using the PRRs, they produce a large
number of functionally distinct host cytokines.20 Research in-
terest in monocyte heterogeneity has gained strong thrust in
the last decade past decade, as a subset-specific contribution of
monocytes to immune stimuli has been postulated.21,22 Pres-
ently, three human monocyte subsets are defined, by virtue of
differential surface expression of LPS receptor CD14 and FcIII
receptor CD16—namely, CD14CD16 (monocytes ex-
pressing CD14 but not CD16), CD14CD16 (monocytes
expressing CD14 and CD16), and CD14CD16 (monocytes
expressing CD16 and low CD14) cells, of which the latter two
subsets are summarized as CD16 monocytes and have been
found to be a minor monocyte population in healthy individ-
uals.23
Although, TLR expression is known to differ among classic
and minor monocyte populations in peripheral blood,24 no
study to date has documented any alteration of the monocyte
subpopulations and the mechanisms underpinning changes in
blood monocyte TLR expression in the pathogenesis of ED.
Therefore, the present study was conducted to identify the
distribution, differential TLR expression, and functional contri-
bution of monocyte subpopulations, as well as the cytokine
production pattern of isolated monocytes after interaction of a
clinically relevant bacterial antigen with TLR in the inflamma-
tory stage of ED.
METHODS
Study Subjects
Nine (eight men, one woman) patients, who received a diagnosis of ED
were recruited from the retina research clinic at the Regional Institute
of Ophthalmology, Kolkata, India, from 2007 through 2010. All nine
patients were in the active stage of ED, as characterized by acute
inflammation of veins in the periphery of the retina. Among them, two
patients (one man, one woman) had inflammation of the small-caliber
vessels, with superficial retinal hemorrhage; two patients (both men)
had large-caliber vessel inflammation, with superficial retinal hemor-
rhage; and the remaining five male patients had large-caliber vessel
inflammation with macular edema. The patients received no medica-
tion before sample collection.
Diagnosis was made for all patients by dilated fundus examination
with direct and indirect ophthalmoscopy, slit lamp biomicroscopy
with 90 D and three-mirror lens, stereoscopic color fundus photog-
raphy, and fluorescein angiography. Other detailed ophthalmic exam-
inations included visual acuity determination by ETDRS chart and
anterior segment evaluation by slit lamp examination. The location and
extent of retinal involvement by vasculitis was documented in all
patients by digital color fundus photography and fluorescein angiogra-
phy.
Nine (seven men, two women) age- and sex-matched healthy
adults, without any history suggestive of ED, attending the outpatient
department of the same institute for treatment of visual difficulty due
to refractive errors without any other systemic inflammatory or ocular
disease provided blood samples and constituted our healthy control
group.
Clinical history was obtained from all participants for the presence
of any associated systemic diseases and use of anti-inflammatory med-
ication. Participants were eligible for this study if they had no smoking
and/or alcohol addiction, had not received any immunosuppressive
therapy, and did not have any coexisting chronic inflammatory disease
or any other recent infection 6 months before collection of the sam-
ples. Subjects with a history of systemic disorders such as, diabetes
mellitus, hypertension, collagen vascular disease, HIV, symptomatic
arthritis, symptomatic malignancy, sarcoidosis, Behc¸et’s disease, sys-
temic lupus erythematosus, Coats’ disease, or syphilis were also ex-
cluded from the study. The study protocol complied with the Decla-
ration of Helsinki and was approved by the Institution’s Ethics
Committee. Informed consent was obtained from each subject.
Isolation of Peripheral Blood Mononuclear Cells
Peripheral blood was collected in an EDTA-coated vial on the day of
diagnosis of ED and from healthy control subjects. Peripheral blood
mononuclear cells (PBMCs) were isolated by density gradient separa-
tion (Ficoll; GE Healthcare, Piscataway, NJ, with Histopaque-1077;
Sigma-Aldrich, St. Louis, MO). Isolated PBMCs were washed with
RPMI1640 medium (Invitrogen-Gibco, Grand Island, NY). This cell
fraction contained monocytes and lymphocytes and was adjusted to
1  106 monocytes/mL, viability of the cells confirmed by trypan blue
exclusion assay. Expression of CD14, CD16, TLR-2, and TLR-4 was
determined, and the remaining cell suspension was used for isolation
and culture for CD14 monocytes and different monocyte subpopula-
tions, as required.
Flow Cytometry
Four-color flow cytometry was performed on freshly isolated PBMCs,
to investigate the cell surface expression of CD14, CD16, TLR-2, and
TLR-4, on monocytes of patients with ED and healthy controls. Briefly,
PBMCs were washed twice with phosphate-buffered saline (PBS; 0.02
M, pH 7.2) and resuspended in PBS containing 2% heat-inactivated fetal
bovine serum (FBS). Fifty microliters of PBMC suspension (1  106
cells/mL) was incubated with primary antibodies for 30 minutes at
room temperature: fluorescein isothiocyanate (FITC)–conjugated anti-
CD14 (clone 61D3, eBioscience, San Diego, CA), phycoerythrin cya-
nine 5 (PECy5)–conjugated anti-CD16 (clone 3G8, BioLegend, San
Diego, CA), allophycocycanin (APC)-conjugated anti-TLR-2 (clone
TL2.1; eBioscience), and phycoerythrin (PE)-conjugated anti-TLR-4
(clone HTA125, eBioscience), along with isotype-matched antibody
controls. After they were washed with PBS, the cells were resuspended
in 400 L PBS containing 2% FBS, and counts were acquired on a
four-parameter flow cytometer (FACSCalibur; BD Biosciences, San
Diego, CA). The monocytes were gated on the basis of parameters
of forward and side light scatter, and acquisition was performed on
5000 gated events. Data analysis was performed with system-
associated software (CellQuest Pro; BD Biosciences). The absolute
count of monocytes was obtained with a hemocytometer counting
chamber, and the monocyte subpopulation counts were calculated
with the percentage distribution obtained from flow cytometry. To
measure TLR fluorescence in monocytes, the cells were plotted on
the basis of their characteristic linear forward and side scatter and
further gated with CD14 and/or CD16 positivity, and then TLR
fluorescence was measured on a logarithmic scale in the FL2 chan-
nel (TLR-4) and FL4 channel (TLR-2). The mean channel fluores-
cence intensity (MFI) derived from the fluorescence histogram was
used to determine the extent of cell surface TLR expression and
expressed as the MFI of specific subtracted from the MFI of respec-
tive isotype control (i.e., MFI-specific staining minus MFI isotype).
Monocyte Separation and Culture
After isolation of PBMCs from healthy controls and ED patients by
density gradient, the monocytes were isolated from the PBMCs by
incubation with magnetic-activated cell sorting (MACS) beads coated
with a monoclonal antibody against human CD14 (Miltenyi Biotec,
Bergisch Gladbach, Germany). Immunomagnetic separation was per-
formed according to the manufacturer’s instructions. Purity 90% was
confirmed by flow cytometry. The cells were adjusted to 1  106
monocytes/mL and cultured in RPMI supplemented with 100 U/mL
penicillin/100 g /mL streptomycin and 10% FBS for 18 hours at 37°C
in 5% CO2, with or without stimulation by 5 g/mL PGN of Staphylo-
coccus aureus (InvivoGen, San Diego, CA), and the cell supernatants
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were collected and stored at 20°C until used for detection of cyto-
kines.
Separation and Culture of
Monocyte Subpopulation
CD14CD16 and CD14CD16 monocytes were selectively isolated
from purified CD14 monocytes (isolated by CD14 microbead and
MACS methodology) of three ED patients by using a CD16 monocyte
isolation kit (Miltenyi Biotec) and MACS methodology, according to the
manufacturer’s instructions. Purity 90% was confirmed by flow cy-
tometry analysis. CD14CD16 and CD14CD16 monocytes were
separately cultured in RPMI supplemented with 100 U/mL penicillin/
100 g/mL streptomycin and 10% FBS for 48 hours at 37°C in 5% CO2
without any stimulation, and the cell supernatants were collected and
stored at 20°C until used for cytokine detection.
Measurement of Cytokines
The presence of cytokines in the culture supernatants and serum was
measured by enzyme-linked immunosorbent assay (ELISAs for TNF-,
IL-6, IFN-, and IL-10; ImmunoTools, Friesoythe, Germany; for IL-1
and TGF-; R&D System, Inc., Minneapolis, MN). Measurements were
performed in duplicate with 100-L sample volume, according to the
manufacturer’s instruction.
Determination of Erythrocyte Sedimentation Rate
and High-Sensitivity C-reactive Protein
The erythrocyte sedimentation rate (ESR) was determined by using the
method of Westergren within 2 hours of obtaining the blood. Briefly,
2 mL of EDTA anticoagulant blood was added to 0.5 mL of 0.85% of
sodium chloride, and the contents of the test tube were mixed gently
for 2 minutes. A standard 200-mm, Westergren tube was filled to the 0
mark, set in a vertical position, and left for 1 hour. The level to which
the red cell column fell at the end of 1 hour was noted, and the result
expressed as millimeters in the first hour.
Serum high-sensitivity C-reactive protein (hsCRP) was then mea-
sured (Magiwel Enzyme Immunoassay; United Biotech, Inc., Mountain
View, CA), per the manufacturer’s instructions.
Inhibition of TLR-2 Expression by siRNA
Human TLR-2-specific or nonspecific control siRNA was transfected
into purified CD14 monocytes isolated from four healthy controls
with a lipophilic transfection reagent (Lipofectamine 2000; Invitro-
gen), according to the protocol of the manufacturer. Briefly, the puri-
fied monocytes (0.5  106 cells/mL) were plated in a 24-well plate and
incubated at 37°C, 5% CO2 for 24 hours. Before the transfection,
cultures were washed, and medium was replaced by 400 L/well of
serum-free RPMI1640 medium (without antibiotics). Serial dilutions of
siRNA were transfected at 10 to 80 nM, with the transfection reagent
(1 L/mL). The transfection reactions were supplemented with 100 L
of FBS after 8 hours and changed to fresh culture medium containing
10% FBS in the next morning. After 48 hours of transfection, cells from
some wells were harvested and examined for surface TLR-2 expression
by flow cytometry. The remaining cells were stimulated with PGN (5
g/mL) for 18 hours, and cell culture supernatants were collected to
measure TNF- by ELISA.
Statistical Analysis
Age and sex differences between the patients and control subjects
were investigated by Student’s t-test and 2 test, respectively. The
significance of differences of measured parameters between corre-
sponding groups of observations was evaluated by the Mann-Whitney
U test, and all values are expressed as the mean  SD. To examine
correlations, we used Spearman’s rank correlation coefficient on the
logged data (Graph-Pad, San Jose, CA). Acceptable significance was
recorded when values reached P  0.05. To determine the minimum
number of patients, yet appropriate sample sizes for our experiments,
we undertook power analysis calculations (PS Power and Sample Size
Calculation software version 3.0.34; http://biostat.mc.vanderbilt.edu/
wiki/Main/PowerSampleSize/ open source software developed by Wil-
liam DuPont and Walton Plummer, Jr., Department of Biostatistics,
Vanderbilt University, Nashville, TN). First, based on our previous
studies, we estimated the effect size among different experimental
units. Thereafter, the sample size was set to nine per group to reject
the null hypothesis at a 5% significance level, ensuring at least 80%
power for each experiment.
RESULTS
Nine patients with the inflammatory stage of ED satisfying the
inclusion and exclusion criteria were studied and compared
with nine healthy age- and sex-matched controls. Demographic
and clinical characteristics indicative of disease progression are
summarized in Table 1.
Increase in Total Circulating Monocytes in
Patients with the Inflammatory Stage of ED,
along with a Shift toward the Nonclassic CD16
Monocyte Subset
Monocytes were analyzed after exclusion of other periph-
eral mononuclear cells shortly after the isolation by side
scatter and forward scatter (Fig. 1A); a higher number of
circulating blood monocytes were found in patients with
the inflammatory stage of ED than were found in healthy
controls (Figs. 1B, 1C).
CD14CD16 (R1), CD14CD16 (R2), and CD14CD16
(R3) monocytes were distinguished by the surface expression
pattern of the LPS receptor CD14 and the FcIII receptor CD16
(Fig. 1D). In healthy controls, CD14CD16 monocytes (R1)
constituted the major population (69.96% in the representative
subject shown), whereas CD14CD16 (R2) and CD14CD16
(R3) were the minor populations (Fig. 1D). However, in a
TABLE 1. Demographic and Clinical Characteristics of the Study Participants
Characteristics
Patients with ED in
Inflammatory Stage Healthy Controls P
Ratio of men to women 8:1 7:2 NS
Age, y 30.2  3.8 30.4  8.6 NS
IL-6, pg/mL 36.15  18.46 6.28  1.71 0.0004
TNF-, pg/mL 21.06  6.72 9.09  1.01 0.0001
hsCRP, mg/L 2.89  0.63 0.89  0.19 0.0001
Total leukocytes, cells/L 8679  2405 6772  1130 0.03
Lymphocyte count, cells/L 1843  395 2150  538 NS
ESR, mm/h 38  12 21  14 0.013
Data are expressed as the mean  SD.
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patient with ED, CD14CD16 (R2) was predominant, being
57.55% versus 7.12% in the control (Fig. 1D).
On average, the percentage of CD14CD16 and
CD14CD16 monocytes was increased in patients compared
with healthy controls (3.99% 0.84% vs. 2.38% 0.83%; P 
0.0041 and 56.83% 6.7% vs. 10.92% 2.98%; P  0.0004,
respectively). In contrast, the proportion of CD14CD16
monocytes significantly decreased in ED patients compared with
controls (27.09% 3.26% vs. 69.06% 4.47%; P  0.0001; Fig.
1E). Significant increases in the CD14CD16 (P 0.0001) and
CD14CD16 (P  0.0008) monocyte subsets were also ob-
served for absolute cell counts, along with a decrease in
CD14CD16 monocytes (P  0.0004) when compared with
the count in the healthy subjects (Fig. 1F).
When the absolute number of total monocytes and different
subsets were related to demographic data, serum inflammatory
cytokine levels, serum hsCRP level, total leukocyte count,
lymphocyte count, and ESR, the CD14CD16 monocyte
subset showed a significant correlation with serum CRP (r 
0.95; P  0.0004) and ESR (r  0.52; P  0.001), which are
accepted clinical indicators of the disease. The CD14CD16
and CD14CD16 monocyte subsets also correlated with se-
rum TNF- (r  0.784; P  0.003 and r  0.4692; P  0.009,
respectively), but not with age, sex, and other studied param-
eters, whereas the CD14CD16 monocytes showed an in-
verse correlation with these markers (Table 2).
Increased Expression of TLR-2 on Isolated Total
Monocytes and CD16 Monocyte Subsets in
Patients with ED
The intensity of TLR-2 and -4 expression in total and different
subsets of the monocyte population was measured shortly after
isolation. Figure 2A shows a representative histogram profile of
FIGURE 1. Flow cytometric determination of monocyte cell subsets among PBMCs in study participants. (A) Representative dot plot depicting
placement of the primary gate around the monocyte population based on forward and side scatter. (B) Proportional and (C) absolute monocyte
counts were obtained with a hemocytometer counting chamber. (D) Representative flow cytometry plots displaying an increase in CD14CD16
(R2) and CD14CD16 (R3) cells among the PBMCs of patients with ED, compared to those of healthy controls. Cumulative data for (E) the
proportions and (F) absolute counts of CD14CD16, CD14CD16, and CD14CD16 monocyte subsets from healthy controls (n  9) and
patients (n  9). P  0.05 indicates significance.
TABLE 2. Correlation Analyses between the Absolute Number of Total Monocytes or the Subpopulation
of Monocytes and Demographic Data, Inflammatory Cytokine Levels, and Other Blood Cells
Total Monocytes
CD14CD16
Monocytes
CD14CD16
Monocytes CD14CD16
r P r P r P r P
Age, y – NS – NS – NS – NS
Sex – NS – NS – NS – NS
IL-6, pg/mL 0.961 0.001 – NS – NS – NS
TNF-, pg/mL 0.894 0.001 0.784 0.003 0.4692 0.009 0.618 0.001
hsCRP, mg/L 0.85 0.0061 0.95 0.0004 0.374 NS 0.82 0.0051
Total leukocytes, cells/L 0.9667 0.0002 – NS – NS – NS
Lymphocyte count, cells/L 0.8167 0.0108 – NS – NS – NS
ESR, mm/h 0.462 0.006 0.52 0.001 – NS – NS
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TLR-2 expression on gated monocytes and the different cell
subsets from healthy controls and patients with ED. A sig-
nificantly higher level of TLR-2 expression, as measured by
MFI, was observed on the total monocytes of patients in the
active stage of ED, compared with age- and sex-matched
healthy controls (P  0.02; Fig. 2B). When comparison was
made between different monocyte subsets in patients, the
average MFI of TLR-2 on CD14CD16 and CD14CD16
monocytes were significantly higher than that of
CD14CD16 monocytes in patients with ED (P  0.028
and P  0.0132, respectively; Fig. 2C). Conversely, in
healthy controls, a higher TLR-2 expression was found in
CD14CD16 monocytes, but the difference in TLR-2 in-
tensity in the different subsets was statistically nonsignifi-
cant (Fig. 2C).
In contrast to TLR-2, staining for TLR-4 revealed low
fluorescence intensity in both study groups, and no statisti-
cally significant intergroup differences and intragroup
monocyte-subset–specific differences were found (Figs.
2D–F).
In addition, in patients with ED, the intensity of TLR-2
expression in total monocytes showed a positive correlation
with serum hsCRP level (r  0.843; P  0.007), whereas no
such correlation was found in expression of TLR-4 on total
monocytes and serum hsCRP (r  0.414; P  0.21; data not
shown).
Increased TLR-2 Induced Cytokine Production by
Monocytes Isolated from ED and Differential
Cytokine Secretion in the Monocyte Subsets
The increased baseline TLR-2 expression on monocytes from
patients with ED may be due to a previous contact with
endotoxin. Hence, we investigated whether TLR-2 engage-
ment results in increased cytokine production. We isolated
circulating monocytes by human CD14-coated microbeads
via MACS methodology in cells from patients and healthy
controls, and then pro- and anti-inflammatory cytokine pro-
duction was determined after cells were cultured with or
without PGN.
In the absence of stimulation, monocytes from ED patients
had increased mean levels of proinflammatory (TNF-, IL-6,
IFN-, and IL-1) and anti-inflammatory (IL-10 and TGF-) cy-
tokines compared with monocytes isolated from healthy con-
trols (Fig. 3A). After activation with PGN, mean levels of all
cytokines increased in both groups compared with unstimu-
lated cells, within each group, but no statistically significant
differences were observed after PGN induction, when the two
groups were compared (Fig. 3B).
Because of the marked accumulation of CD16 monocytes
in inflammatory phases of ED, we further sought to define the
likely function of this subset in the pathogenesis of this disease.
FIGURE 2. Flow cytometric analysis
of TLR-2 and -4 expression on mono-
cytes isolated from patients with ED
and healthy controls. (A) Representa-
tive histograms showing TLR-2 ex-
pression in total and different subsets
of monocyte population. (B) TLR-2
expression in total monocytes was
higher in patients with ED than in
healthy controls. (C) TLR-2 fluores-
cence intensity on CD16 mono-
cytes was significantly higher than
that of CD16 monocytes in patients
with ED, but no significant subset-
specific differences in TLR-2 expres-
sion were found in healthy controls.
(D) Representative histograms show
TLR-4 expression in total and differ-
ent subsets of the monocyte popula-
tion. (E) No significant differences
were found between patients and
health controls in TLR-4 expression
on total monocytes. (F) There were
no differences in TLR-4 fluorescence
intensity on different monocyte sub-
sets in both groups. Fluorescence
intensity of cell surface TLR was
expressed as the difference be-
tween the mean fluorescence inten-
sity (MFI) of staining with anti-
TLR-2 or anti-TLR-4 antibody and
isotype-matched control antibody
(MFIspecific staining  MFIisotype). P 
0.05 indicates significance. ns, non-
significant.
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CD16 and CD16 monocytes were isolated from three pa-
tients by MACS methodology, and baseline cytokine secretion
was measured after 48 hours of culture without any stimula-
tion. The CD16 monocytes were the major producers of
TNF-, IL-6, and IFN-, compared with the CD16 subgroup
(P  0.0001, P 0.008, and P 0.0006, respectively). CD16
monocytes, on the other hand, were the main producers of
IL-1 (P  0.03) and TGF- (P  0.04). Moreover CD16, but
not CD16, monocytes were the only producers of the anti-
inflammatory cytokine IL-10 (Fig. 3C).
Relationship between TLR-2 Expression and
Ligand-Induced Cytokine Production
Spearman’s rank correlation analysis was performed to deter-
mine the relationship between surface TLR-2 expression on
total isolated circulating monocytes and response to the TLR-2
ligand. A significant positive correlation was noted between
cell surface TLR-2 expression and PGN-induced TNF-  produc-
tion (r  0.85; P  0.0061; Fig. 4A) by monocytes isolated
from healthy controls. However, no significant correlation was
found between TLR-2 expression and PGN-induced TNF- pro-
duction (r  0.553; P  0.1328; Fig. 4B) by total monocytes
isolated from ED patients.
Diminished Activation by PGN Resulting from
Forced Reduction of TLR-2 Expression
Since the relationship of TLR-2 expression on monocytes and
activation by PGN was not consistent between healthy controls
and ED patients, experiments were performed to directly de-
termine the effects of forced reduction of TLR-2 expression on
PGN-induced activation. Forty-eight hours after introducing
siRNA into monocytes isolated from four different healthy
controls, cell surface TLR-2 expression was significantly re-
duced by TLR-2-specific siRNA (P  0.003 at concentration of
siRNA 20 nM, P  0.002 at concentration of siRNA 40 nM, and
P  0.001 at concentration of siRNA60 nM, when compared
with nontransfected controls), but not by control siRNA (Fig.
4C). PGN induced TNF- production demonstrated a signifi-
cant dose-dependent reduction (P  0.0016 at concentration
of siRNA 20 nM and P  0.001 at a concentration of siRNA 
40 nM when compared with nontransfected controls) after the
introduction of TLR-2-specific siRNA into monocytes isolated
from healthy controls, but no reduction was detected in the
nonspecific control siRNA (Fig. 4D). These results demonstrate
that the forced reduction of TLR-2 expression in monocytes
resulted in diminished PGN mediated secretion of TNF-.
DISCUSSION
The notion that inflammatory mechanisms play an important
role in the progression of the pathologic angiogenesis, includ-
ing retinal neovascularization, has emerged as a major para-
digm shift in our understanding of disease pathogenesis. In an
effort to eliminate invading pathogens, inflammation is usually
the final common pathway used, and both innate and adaptive
immune responses are known to trigger inflammation. Consid-
ering the significant impact of ED, including visual disability
and blindness, investigation of the basic mechanisms underly-
ing the ocular inflammation linked with this disease is war-
ranted. Association of systemic inflammation with the inflam-
matory stage of ED has been established by the presence of
elevated levels of C-reactive protein9 or circulating IL-6 as a
marker.25 However, the findings of association between sys-
temic and local inflammation in ED is limited. Only one study
has described the association between increased levels of
TNF- with severity of retinal periphlebitis in patients with
ED.26 In concurrence, we also noted that high levels of sys-
temic inflammatory markers correlated with an increased se-
verity of retinal inflammation in patients with ED (data not
shown). However, inflammation is not only a phenomenon of
plasma acute-phase proteins but also of alteration in circulating
pools of blood immune cells, including monocytes.
In this study, we demonstrated that number of monocytes
are increased in circulation during the active stage of ED;
strikingly, we observed a strong shift toward the CD16mono-
cytes, particularly the CD14CD16monocyte subset. These
CD16 cells have a distinct phenotype and are efficient pro-
ducers of proinflammatory cytokines on TLR engagement,27
whereas they weakly secrete the anti-inflammatory cytokine
IL-10.28 They also have high endothelial affinity conferred by
FIGURE 3. Monocytes were function-
ally active in patients with a differen-
tial release of distinct cytokines by
monocyte subpopulation. (A) Cyto-
kine release of isolated monocytes
from healthy controls and patients
with ED (18-hour culture) without
stimulation and (B) after stimulation
with 5 g/mL PGN for 18 hours. (C)
Cytokine release by purified mono-
cyte subsets after 48-hour culture
without stimulation. P 0.05 indi-
cates significance. ns, nonsignificant.
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their surface expression of chemokine receptors and adhesion
molecules such as CX3CR1, CCR5, VLA-4, and ICAM-1.29–31
Furthermore, the “patrolling” behavior of the mouse counter-
part of CD16 monocytes has been described by investigators,
who found that these monocytes crawl along the endothelium
and, on inflammatory stimulation, rapidly gain access to the
endothelium and home to sites of endothelial activation in a
CX3CR1-dependent manner. There, they secrete MMP-9,
CCL-2, and IL-6 with the ability to propagate further vascular
damage through the recruitment of T-lymphocytes and addi-
tional monocytes.32,33
Endothelial dysfunction, a concomitant effect of endothelial
cell activation, is the ultimate fate of many vasoproliferative
retinal disorders, including ED.34 The evidence makes a good
case for a probable role of CD16 monocytes in this disease.
Although, the involvement of MMP-935 and inflammatory cyto-
kines36 has been established in the pathogenesis of ED, no
previous reports have confirmed the involvement of cell adhe-
sion molecules. Keeping in mind their important role in inflam-
matory ocular neovascularization events,37 participation of
these adhesion molecules with immunopathogenesis of ED
cannot be ruled out and is a subject of ongoing research for
better understanding of the pathologic course of these dis-
eases. The associated data from the present study (i.e., relative
abundance of CD16 monocytes) correlated with circulating
proinflammatory cytokines and parameters indicative of dis-
ease progression, whereas CD14CD16 monocytes showed
an inverse correlation with these markers, and in view of the
endothelial activation capability of these minor subsets, sup-
port the relevance of CD16 monocytes to the inflammatory
stage and may be suggested to be stimulators of endothelial
damage in the advanced stage of ED.
In addition, elevated levels of cell surface TLR-2 expres-
sion on systemic circulating monocytes, but not TLR-4, was
found in the inflammatory stage of ED. Interestingly, expres-
sion of TLR-2 on various subsets of monocytes from ED
patients was different from that of healthy controls. TLR2
expression was significantly higher in CD16 compared
with CD16 monocytes in ED patients. In contrast, the
intensity of TLR-4 was similar in both monocyte subsets
from ED patients and healthy controls. In addition, the
intensity of the TLR-2, but not the intensity of the TLR-4,
expressed on total monocytes was found to correlate with
serum CRP level in ED patients. Taken together, the data
suggest that TLR-2 expression may be enhanced during
CD16 monocyte maturation in vivo in association with
disease activity, but TLR-4 expression remained unchanged.
These observations further support the proposed concept of
M. tuberculosis association and suggest involvement of
TLR-2 activation by respective microbial products or their
PAMPs in the pathogenesis of ED.
Because we assumed that the increased TLR-2 expression
on monocytes isolated from patients was a result of previous
contact, we proceeded to determine whether TLR-2 engage-
ment results in increased cytokine expression by monocytes.
We also wanted to determine the functional contribution of
different monocyte subsets in the pathogenesis of ocular in-
flammation in ED. Accordingly, cytokine production was mea-
FIGURE 4. Relation between TLR-2 expression and PGN-induced TNF- production in monocytes. Cor-
relation of the cell surface expression of TLR-2 with production of TNF- after PGN stimulation in
monocytes isolated from (A) healthy controls (n  9) and from (B) patients with ED (n  9). The solid
line represents the linear regression curve of best fit. (C) Monocytes isolated from healthy controls (n 
4) were transfected with different concentrations of control siRNA or TLR-2-specific siRNA and examined
for cell surface expression of TLR-2. (D) TNF- production by different concentrations of control or
TLR-2-specific siRNA–transfected monocytes, isolated from healthy controls, after 5 g/mL PGN stimula-
tion. The cell surface TLR-2 expression was determined by flow cytometry analysis, and TNF- concen-
tration was determined by ELISA. Results are presented as the percentage of TLR-2 expression and the
percentage of TNF- production normalized to the nontransfected control (100%). The P values in
parentheses indicate a significant difference (P 0.05) between the transfected and nontransfected
controls.
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sured in total monocytes, isolated from patients and matched
controls, with and without PGN stimulation, and in monocyte
subsets in ED patients without PGN stimulation.
At baseline, total monocytes from ED patients secreted
significantly higher amounts of inflammatory mediators than
healthy subjects. These findings are in good agreement with
the hypothesis that increased productions of inflammatory
cytokines are a crucial mechanism in development of perireti-
nal neovascularization and worsen outcome of ED.34 Further
dissecting the diverse functional capacities of both monocyte
subsets in vitro confirmed that the CD16 monocyte subset is
the main source of proinflammatory mediators, thereby per-
petuating the chronic inflammatory response in the retina. This
conclusion is corroborated by correlating between circulating
CD16 monocyte counts and levels of serum TNF- in ED
patients.
After PGN stimulation, cytokine production by monocytes
increased in all study groups, and no significant intragroup
differences were found. It is thought that monocytes isolated
from patients are inherently more responsive than those ob-
tained from healthy controls, due to the possibility that the cell
surface expression of TLR controls the ligand-induced down-
stream response. Forced diminution of TLR-2 expression on
monocytes in our study resulted in a decreased response to
PGN, also supporting the hypothesis that increased expression
of TLR-2 results in an enhanced response to TLR-2 ligand.
Conversely, when we examined the relationship of surface
expression of TLR-2 on monocytes with the levels of cytokines
induced by stimulation with TLR-2 ligand, a significant positive
association was found in monocytes isolated from healthy
controls but not in monocytes from patients. The data revealed
that the PGN-induced responses of monocytes isolated from
patients, although increased compared with those of unstimu-
lated monocytes in vitro, were less than would have been
expected of monocytes isolated from healthy controls at com-
parable levels of cell surface TLR-2.
These findings are of relevance, given the further evidence
supporting the role of a microbial trigger and, in particular,
Gram-positive bacteria in the development of ED. As all study
patients had active inflammation at the time of sampling, it is
feasible that prior in vivo exposure to potential endogenous
TLR-2 ligands induced tolerance to repeat stimulation,38,39 pos-
sibly accounting for the lack of association between TLR-2
expression and response to TLR-2 ligand in ED patients. The
existence of TLR-2 ligand in ocular tissue of ED patients has not
yet been established. Analysis of vitreous collected from ED
patients at the time of vitrectomy by molecular biology tech-
niques has detected the presence of Mycobacterium DNA
suggesting the existence of Mycobacterium-derived ligands.5,6
However, reduced response to PGN is a transient state, and the
present study did not demonstrate a dynamic change in TLR
function in ED. It is conceivable that the kinetics of TLR-2
expression, along with cytokine production, is different at later
stages of progression of ED and should be investigated in the
future.
In summary, the findings of the present study indicate that
nonclassic CD16 monocytes are crucial regulators in the
pathogenesis of ED and act by secreting an abundance of
cytokines perpetuating the retinal inflammatory process. Fur-
thermore, this study also implies a role for TLR-2 activation in
the pathogenic outcome of ED. Demonstration of increased
TLR-2 expression on systemic immune cells in ED together
with a functional state of reduced TLR-2 ligand response pro-
vides further evidence of the role of Mycobacterium in the
development of Eales’ disease.
Acknowledgments
The authors thank the Regional Institute of Ophthalmology for allow-
ing them to contact the patients and to obtain information from their
clinical records.
References
1. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ra-
makrishnan S. Eales’ disease: an update. Surv Ophthalmol. 2002;
47:197–214.
2. Das T, Biswas J, Kumar A, et al. Eales’ disease. Indian J Ophthal-
mol. 1994;42:3–28.
3. Abu El- Asrar AM, Al- Kharashi SA. Full panretinal photocoagulation
and early vitrectomy improve prognosis of retinal vasculitis asso-
ciated with tuberculoprotein hypersensitivity (Eales’ disease). Br J
Ophthalmol. 2002;86:1248–1251.
4. Biswas J, Jain M, Narain S, Roy S, Madhavan HN. Evaluation of
lymphocytes proliferation assay to purified protein derivative, en-
zyme linked immunosorbent assay and tuberculin hypersensitivity
in Eales’ disease. Indian J Ophthalmol. 1997;45:93–97.
5. Madhavan HN, Therese KL, Gunisha P, Jayanthi U, Biswas J. Poly-
merase chain reaction for detection of Mycobacterium tuberculo-
sis in epiretinal membranes in Eales’ disease. Invest Ophthalmol
Vis Sci. 2000;41:822–825.
6. Therese KL, Deepa P, Therese J, Bagyalakshmi R, Biswas J, Mad-
havan HN. Association of mycobacteria with Eales’ disease. Indian
J Med Res. 2007;126:56–62.
7. Biswas J, Mukesh BN, Naratin S, et al. Profiling of human leukocyte
antigens in Eales’ disease. Int Ophthalmol. 1998;21:277–281.
8. Rosen PH, Spalton DJ, Gaham EM. Intraocular tuberculosis. Eye.
1990;4:486–492.
9. Saxena S, Kumar D, Kapoor S, Jain A. C-reactive protein in Eales’
disease. Ann Ophthalmol. 2002;34:179–180.
10. Saxena S, Kumar D. A new staging system for idiopathic retinal
periphlebitis. Eur J Ophthalmol. 2004;14:236–239.
11. Roach JC, Glusman G, Rowen L, et al. The evolution of vertebrate
Toll-like receptors. Proc Natl Acad Sci USA. 2005;102:9577–9582.
12. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate
immunity. Cell. 2006;124:783–801.
13. Waltenbaugh C, Doan T, Melvold R, Viselli S. Immunology. 2008
Lippincott’s Illustrated Reviews. Philadelphia: Wolters Kluwer
Health/Lippincott Williams & Wilkins; 2008:17.
14. Cole JE, Georgiou E, Monaco C. The expression and functions of
Toll-like receptors in atherosclerosis. Mediators Inflamm. 2010;
2010:393946.
15. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differ-
entially activate human dendritic cells. J Biol Chem. 2001;276:
37692–37699.
16. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton
MJ. Human toll-like receptors mediate cellular activation by Myco-
bacterium tuberculosis. J Immunol. 1999;163:3920–3927.
17. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mecha-
nisms triggered by microbial lipoproteins through toll-like recep-
tors. Science. 1999;285:732–736.
18. Noss EH, Pai RK, Sellati TJ, et al. Toll-like 2-dependent inhibition of
macrophage class II MHC expression and antigen processing by
19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol.
2001;167:910–918.
19. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton
MJ. The CD14 ligands lipoarabinomannan and lipopolysaccharide
differ in their requirement for Toll-like receptors. J Immunol.
1999;163:6748–6755.
20. Gordon S. Pattern recognition receptors, doubling up for the
innate immune response. Cell. 2002;111:927–930.
21. Passlick B, Flinger D, Ziegler-Heitbrock HWL. Identification and
characterization of a novel monocyte subpopulation in human
peripheral blood. Blood. 1989;74:2527–2534.
22. Wang SV, Mak KL, Chen LY, Chou MP, Ho CK. Heterogeneity of
human blood monocytes: two subpopulations with different size,
phenotypes and functions. Immunology. 1992;77:298–303.
IOVS, August 2011, Vol. 52, No. 9 Toll-like Receptor in Eales’ Disease 6947
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933460/ on 08/22/2017
23. Ziegler-Heitbrock L. The CD14 CD16 blood monocytes: their
role in infection and inflammation. J Leukoc Biol. 2007;81:584–
592.
24. Skinner NA, Maclsaac CM. Hamilton JA, Visvanathan K. Regulation
of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16 mono-
cytes in response to sepsis-related antigens. Clin Exp Immunol.
2005;141:270–278.
25. Sen A, Paine SK, Chowdhury IH, et al. Impact of IL-6 promoter
polymorphism and serum IL-6 level on acute inflammation and
neovascularization stage of patients with Eales’ disease. Mol Vis. In
press.
26. Saxena S, Pant AB, Khanna VK, et al. Tumor necrosis factor--
mediated severity of idiopathic retinal periphlebitis in young
adults (Eales’ disease): implication for anti-TNF- therapy. J Ocul
Biol Dis Infor. 2010;3:35–38.
27. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14
() CD16 () DR () monocytes are a major source of TNF
J Immunol. 2002;168:3536–3542.
28. Szaflarskaa A, Baj-Krzyworzekaa M, Siedlara M, et al. Antitumor
response of CD14/CD16 monocyte subpopulation. Exp Hema-
tol. 2004;32:748–755.
29. Kawanaka N, Yamamura M, Aita T, et al. CD14, CD16 blood
monocytes and joint inflammation in rheumatoid arthritis. Arthri-
tis Rheum. 2002;46:2578–2586.
30. Ancuta P, Rao R, Moses A, et al. Fractalkine preferentially mediates
arrest and migration of CD16 monocytes. J Exp Med. 2003;16;
197:1701–1707.
31. Steppich B, Dayyani F, Gruber R, Lorenz R, Mack M, Ziegler-
Heitbrock HW. Selective mobilization of CD14CD16monocytes
by exercise. Am J Physiol Cell Physiol. 2000;279:C578–C586.
32. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and
tissues by a population of monocytes with patrolling behavior.
Science. 2007;317:666–670.
33. Ancuta P, Wang J, Gabuzda D. CD16 monocytes produce IL-6, CCL2,
and matrix metalloproteinase-9 upon interaction with CX3CL1-
expressing endothelial cells. J Leukoc Biol. 2006;80:1156–1164.
34. Sen A, Paine SK, Chowdhury IH, et al. Association of interferon-
gamma, interleukin-10, and tumor necrosis factor-alpha gene poly-
morphisms with occurrence and severity of Eales’ disease. Invest
Ophthalmol Vis Sci. 2011;52:171–178.
35. Sen A, Paine SK, Chowdhury IH, et al. Assessment of gelatinase
and tumor necrosis factor- level in the vitreous and serum of
patients with Eales disease: role of inflammation-mediated an-
giogenesis in the pathogenesis of Eales disease. Retina. 2011;
31:1412–1420.
36. Saxena S, Pant AB, Khanna VK, et al. Interleukin-1 and tu-
mor necrosis factor-alpha: novel targets for immunotherapy
in Eales disease. Ocul Immunol Inflamm. 2009;17:201-
206.
37. Zhu SN, Dana MR. Expression of cell adhesion molecules on
limbal and neovascular endothelium in corneal inflammatory
neovascularization. Invest Ophthalmol Vis Sci. 1999;40:1427–
1434.
38. Kilmartin B, Reen DJ. HSP60 induces self-tolerance to repeated
HSP60 stimulation and cross-tolerance to other pro-inflammatory
stimuli. Eur J Immunol. 2004;34:2041–2051.
39. Sato S, Nomura F, Kawai T, et al. Synergy and cross-tolerance
between Toll-like receptor (TLR)2 and TLR4-mediated signaling
pathways. J Immunol. 2000;165:7096–7102.
6948 Sen et al. IOVS, August 2011, Vol. 52, No. 9
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933460/ on 08/22/2017
